Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted Income from Continuing Operations of -$58.37 million for Q2 2026, compared with $22.5 million a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Income from Continuing Operations at Supernus Pharmaceuticals was -$85.12 million; for FY2025, it was -$38.55 million.
- In prior years, Supernus Pharmaceuticals' Income from Continuing Operations was $73.87 million in FY2024, $1.32 million in FY2023 (-97.8%), $60.71 million in FY2022 (+13.6%) and $53.42 million in FY2021 (-57.9%).
- The Q2 2026 figure stands as the lowest quarterly Income from Continuing Operations in data going back to Q1 2011.
- The strongest year-over-year quarter for Income from Continuing Operations in the past five years was Q4 2022, with growth of 943.4%; the weakest was Q1 2024, with a decline of 99.3%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Supernus Pharmaceuticals | 2.50 Bn | 1.16 Bn | 185.39 Mn | -58.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -58.37 Mn |
| Dec 31, 2025 | -4.13 Mn |
| Sep 30, 2025 | -45.12 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | -11.83 Mn |
| Dec 31, 2024 | 15.38 Mn |
| Sep 30, 2024 | 38.50 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | -16.01 Mn |
| Jun 30, 2023 | -827,000.00 |
| Mar 31, 2023 | 16.95 Mn |
| Dec 31, 2022 | 25.48 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 25.62 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 23.73 Mn |
API Access
Supernus Pharmaceuticals Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();